MoonLake's positive HS Phase 3 data and short squeeze drive 17% AVTX surge
Avalo Therapeutics, Inc. is a precision medicine company in the clinical development phase, dedicated to identifying, advancing, and marketing specialized treatments for patients experiencing critical unmet medical needs across the fields of immunology, immuno-oncology, and rare genetic disorders. Among its key pipeline assets is AVTX-002, a fully human monoclonal antibody designed to inhibit LIGHT. This drug is currently undergoing Phase II clinical trials for non-eosinophilic asthma and inflammatory bowel diseases, specifically moderate to severe Crohn's disease and ulcerative colitis. Furthermore, AVTX-002 is also being investigated in Phase III for its potential to treat acute respiratory distress syndrome caused by COVID-19. The company is also advancing AVTX-007, a fully human monoclonal antibody targeting IL-18, which is progressing through Phase I clinical studies for Still's disease, encompassing both adult-onset Still's disease and systemic juvenile idiopathic arthritis. Avalo's late-stage pipeline includes two products addressing rare genetic conditions, both in Phase III clinical trials: AVTX-801, a D-galactose substrate replacement therapy for phosphoglucomutase 1 deficiency (PGM1), also known as PGM1-CDG; and AVTX-803, an L-fucose substrate replacement therapy intended for LADII, medically referred to as SLC35C1-CDG. Established in 2011, the corporation initially operated as Cerecor Inc. before rebranding as Avalo Therapeutics, Inc. in August 2021. Its main operations are situated in Rockville, Maryland.
| Metric | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $441.00K | $1.92M | $18.05M | $5.40M | $6.70M | $6.75M | $18.33M | $27.81M |
| Cost of Revenue | $-366.00K | $1.28M | $3.43M | $1.49M | $300.00K | $-566.52K | $7.48M | $635.65K |
| Gross Profit | $807.00K | $640.00K | $14.62M | $3.91M | $6.40M | $7.32M | $10.85M | $27.18M |
| Gross Margin | 182.99% | 33.26% | 80.98% | 72.38% | 95.52% | 108.39% | 59.19% | 97.71% |
| Operating Expenses | $69.32M | $27.99M | $52.06M | $86.04M | $6.40M | $23.45M | $50.16M | $13.29M |
| Operating Income | $-68.51M | $-27.35M | $-37.44M | $-82.13M | N/A | $-16.14M | $-39.31M | $13.89M |
| Operating Margin | -15535.60% | -1421.57% | -207.41% | -1521.56% | 0.00% | -239.06% | -214.52% | 49.94% |
| Net Income | $-35.13M | $-31.54M | $-41.66M | $-84.38M | $-63.50M | $-16.07M | $-40.05M | $11.87M |
| Net Margin | -7965.76% | -1639.50% | -230.78% | -1563.10% | -947.90% | -238.10% | -218.55% | 42.68% |
| EPS (Basic) | $-4.32 | $-113.58 | $-1062.65 | $-2330.66 | $-2523.77 | $-819.74 | $-3317.28 | $1856.88 |
| EBITDA | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Stock Option Compensation Expense | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Price To Earnings Ratio | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Price To Sales Ratio | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Shares Outstanding | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Market Capitalization | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |